ArticleAnnals of medicine2026
Clinical associations during the year before Parkinson's disease diagnosis in Taiwan: a nationwide claims-based case-control study.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCharacterizing clinical associations before Parkinson's disease (PD) diagnosis may improve understanding of the diagnostic window in real-world care. Using nationwide claims data from Taiwan, clinical patterns and medication exposures recorded before incident PD were examined, and secondary neurological outcomes and all-cause mortality were evaluated during follow-up.
methodsA retrospective, population-based case-control study was conducted using Taiwan's National Health Insurance Research Database (2000-2016). Incident PD cases were matched 1:4 to controls using a two-stage approach: frequency matching on birth year and sex, followed by propensity score matching for healthcare utilization and selected comorbidities. Associations between prespecified comorbidities, medication exposures, and incident PD were estimated using multivariable logistic regression, while Kaplan-Meier methods and Cox proportional hazards models assessed secondary neurological outcomes and all-cause mortality.
resultsA total of 2124 patients with PD and 8496 matched controls were included. Within the one-year pre-diagnostic window, incident PD was significantly associated with head injury (adjusted odds ratio [aOR] 2.16), ischemic stroke (aOR 2.90), hepatitis C virus infection (aOR 1.40), hospitalization for bacterial infection (aOR 1.43), chronic exposure to propranolol (aOR 1.72), and proton pump inhibitors (aOR 1.24), whereas hyperlipidemia showed an inverse association (aOR 0.67). During follow-up, PD patients had higher adjusted hazards for secondary neurological outcomes (adjusted hazard ratio [aHR] 2.24; 95% confidence interval [CI] 1.94-2.58) and all-cause mortality (aHR 1.72; 95% CI 1.57-1.89) than controls.
conclusionsThese findings highlight priority variables for understanding the complex clinical landscape preceding a formal PD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.